Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patidegib Gel 2% in Gorlin Syndrome
NCT06050122Phase 3Completed
- Sponsor
- Sol-Gel Technologies
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of patidegib in nevoid basal cell carcinoma syndrome (NBCCS), sponsored by Sol-Gel Technologies. Started Mar 2024; status: completed.
02
Drugs
patidegib
03
Conditions
nevoid basal cell carcinoma syndrome (NBCCS)
Beyond the preview
Go deeper on NCT06050122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050122.